Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 89,000 shares of the company’s common stock, at a per share exercise price of $6.48, the closing trading price on December 6, and restricted stock units to acquire 44,500 shares of the company’s common stock.
December 9, 2019
· 1 min read